February 26, 2024
GLP-1s are drugs proven to treat diabetes. But with high costs, increased use for other purposes and clinical uncertainty, GLP-1s are not without controversy. This brief underscores the history of these medications and makes policy recommendations to ensure patients are receiving the right drugs at the right time.
New from ACHP:
- ACHP Statement on CY2026 MA & Part D Rule
- ACHP Amplifies the Voice of Nonprofit Health Plans with Three New Members
- ACHP Joins Hospital-at-Home Sign-On Letter to Congress
- ACHP Response Letter to 2026 Notice of Benefit and Payment Parameters
- It’s Too Early to Claim Victory on Raising the MA Quality Bar
- ACHP Signs Joint Letter on Good Faith Compliance in Mental Health Parity Final Rule
